Bristol-Myers Squibb Co.

NYSE: BMY
$54.17
+$1.38 (+2.6%)
Real time price as of March 30, 2020 1:19 pm EDT
As the U.S. economy starts to shut down, cash is king. These 10 public corporations have a tremendous amount of cash on their balance sheets.
Douglas A. McIntyre
Monday's top analyst calls included AbbVie, AES, AT&T, Boeing, Carnival, CME, Coca-Cola, Comcast, Honeywell, Lululemon Athletica, Netflix, Shopify, Starbucks and Twitter.
Jon C. Ogg
With interest rates still at generational lows, investors looking for income from stocks may be in the best place in a while. High-yielding, safer blue chips are available at rock bottom prices.
Lee Jackson
The February 28 short interest data have been compared with the previous figures, and short interest in these top pharmaceutical stocks decreased.
Chris Lange
These five companies pay dividends, have shares that are rated Buy, tend to do well when the federal funds rate is cut and make good sense for worried investors now.
Lee Jackson
The February 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Chris Lange
With billions of dollars flowing in, it has become impossible to ignore the ESG trend. These 15 top ESG stocks appear to be undervalued against the performance of the broader markets.
Jon C. Ogg
The January 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Chris Lange
24/7 Wall St. screened the Merrill Lynch health care research database looking for large pharmaceutical leaders that also pay solid and dependable dividends. These five make sense for growth and...
Lee Jackson
24/7 Wall St. has put together a preview of Disney, Ford, Merck, Uber and some of the other most anticipated earnings reports that are expected this week.
Chris Lange
The January 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Chris Lange
The December 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Chris Lange
The December 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Chris Lange
Independent research firm Argus sees better than 25% potential upside for Bristol-Myers Squibb in the coming year.
Jon C. Ogg
The top analyst upgrades, downgrades and initiations for Friday included Adobe, Biogen, Bristol-Myers, Broadcom, Charles Schwab, Ciena, Etsy, Gilead, Oracle, Sarepta, Snap and Wayfair.
Jon C. Ogg